191 related articles for article (PubMed ID: 29126924)
21. Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/beta-catenin pathway.
Yanamoto S; Kawasaki G; Yamada S; Yoshitomi I; Yoshida H; Mizuno A
Oral Oncol; 2009 Jun; 45(6):521-5. PubMed ID: 18804405
[TBL] [Abstract][Full Text] [Related]
22. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.
Zhou B; Liu X; Mo X; Xue L; Darwish D; Qiu W; Shih J; Hwu EB; Luh F; Yen Y
Cancer Res; 2003 Oct; 63(20):6583-94. PubMed ID: 14583450
[TBL] [Abstract][Full Text] [Related]
23. Triptolide inhibits viability and induces apoptosis in liver cancer cells through activation of the tumor suppressor gene p53.
Sun YY; Xiao L; Wang D; Ji YC; Yang YP; Ma R; Chen XH
Int J Oncol; 2017 Mar; 50(3):847-852. PubMed ID: 28098861
[TBL] [Abstract][Full Text] [Related]
24. Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells.
Li X; Zhu Y; He H; Lou L; Ye W; Chen Y; Wang J
Biochem Biophys Res Commun; 2013 Jun; 436(2):259-64. PubMed ID: 23726914
[TBL] [Abstract][Full Text] [Related]
25. Effect of high-risk human papillomavirus oncoproteins on p53R2 gene expression after DNA damage.
Lembo D; Donalisio M; Cornaglia M; Azzimonti B; Demurtas A; Landolfo S
Virus Res; 2006 Dec; 122(1-2):189-93. PubMed ID: 16872707
[TBL] [Abstract][Full Text] [Related]
26. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage.
Tanaka H; Arakawa H; Yamaguchi T; Shiraishi K; Fukuda S; Matsui K; Takei Y; Nakamura Y
Nature; 2000 Mar; 404(6773):42-9. PubMed ID: 10716435
[TBL] [Abstract][Full Text] [Related]
27. SC-III3, a novel scopoletin derivative, induces cytotoxicity in hepatocellular cancer cells through oxidative DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.
Zhao P; Chen L; Li LH; Wei ZF; Tong B; Jia YG; Kong LY; Xia YF; Dai Y
BMC Cancer; 2014 Dec; 14():987. PubMed ID: 25527123
[TBL] [Abstract][Full Text] [Related]
28. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Link PA; Baer MR; James SR; Jones DA; Karpf AR
Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
[TBL] [Abstract][Full Text] [Related]
29. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis.
Zhang DM; Liu JS; Tang MK; Yiu A; Cao HH; Jiang L; Chan JY; Tian HY; Fung KP; Ye WC
Eur J Pharmacol; 2012 Oct; 692(1-3):19-28. PubMed ID: 22841670
[TBL] [Abstract][Full Text] [Related]
30. Mcl-1 as a potential therapeutic target for human hepatocelluar carcinoma.
Yu Q; Liu ZY; Chen Q; Lin JS
J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):494-500. PubMed ID: 27465322
[TBL] [Abstract][Full Text] [Related]
31. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
[TBL] [Abstract][Full Text] [Related]
32. Silencing of myeloid cell leukemia-1 by small interfering RNA improves chemosensitivity to etoposide in u-937 leukemic cells.
Jafarlou M; Baradaran B; Shanehbandi D; Saedi TA; Jafarlou V; Karimi P; Othman F
J Biol Regul Homeost Agents; 2016; 30(1):55-65. PubMed ID: 27049076
[TBL] [Abstract][Full Text] [Related]
33. Increase of Intracellular Cyclic AMP by PDE4 Inhibitors Affects HepG2 Cell Cycle Progression and Survival.
Massimi M; Cardarelli S; Galli F; Giardi MF; Ragusa F; Panera N; Cinque B; Cifone MG; Biagioni S; Giorgi M
J Cell Biochem; 2017 Jun; 118(6):1401-1411. PubMed ID: 27859531
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of the Arg/N-degron Pathway Sensitizes Cancer Cells to Chemotherapy In Vivo.
Leboeuf D; Abakumova T; Prikazchikova T; Rhym L; Anderson DG; Zatsepin TS; Piatkov KI
Mol Ther; 2020 Apr; 28(4):1092-1104. PubMed ID: 32087767
[TBL] [Abstract][Full Text] [Related]
35. Inter-regulation of IGFBP1 and FOXO3a unveils novel mechanism in ursolic acid-inhibited growth of hepatocellular carcinoma cells.
Yang LJ; Tang Q; Wu J; Chen Y; Zheng F; Dai Z; Hann SS
J Exp Clin Cancer Res; 2016 Mar; 35():59. PubMed ID: 27036874
[TBL] [Abstract][Full Text] [Related]
36. Dendrosomal curcumin nanoformulation modulate apoptosis-related genes and protein expression in hepatocarcinoma cell lines.
Montazeri M; Sadeghizadeh M; Pilehvar-Soltanahmadi Y; Zarghami F; Khodi S; Mohaghegh M; Sadeghzadeh H; Zarghami N
Int J Pharm; 2016 Jul; 509(1-2):244-254. PubMed ID: 27234697
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of Kinesin spindle protein inhibits proliferation, induces apoptosis and increases chemosensitivity in hepatocellular carcinoma cells.
Doan CC; Doan NT; Nguyen QH; Nguyen MH; Do MS; Le VD
Iran Biomed J; 2015; 19(1):1-16. PubMed ID: 25605484
[TBL] [Abstract][Full Text] [Related]
38. Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53.
Calvisi DF; Simile MM; Ladu S; Frau M; Evert M; Tomasi ML; Demartis MI; Daino L; Seddaiu MA; Brozzetti S; Feo F; Pascale RM
Hepatology; 2011 Apr; 53(4):1226-36. PubMed ID: 21480327
[TBL] [Abstract][Full Text] [Related]
39. [Effect of Na(+)/K(+)-ATPase alpha1 siRNA and ouabain upon cell cycle in human hepatoma HepG2 cell and its mechanism].
Xu ZW; Wang FM; Xu RC; Hu WL; Chen XY
Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(12):813-7. PubMed ID: 20450619
[TBL] [Abstract][Full Text] [Related]
40. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
